July 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Melissa Leichter Announces The Newly FDA Approved Subcutaneous Prophylactic Treatment for Hemophilia A or B

Melissa Leichter/LinkedIn

Aug 1, 2025, 17:31

Melissa Leichter Announces The Newly FDA Approved Subcutaneous Prophylactic Treatment for Hemophilia A or B

Melissa Leichter, Rare Disease Executive, Novo Nordisk, shared a proud announcement post on LinkedIn:

”Today marks an exciting step forward for the hemophilia community. The FDA has approved our new subcutaneous prophylactic treatment for patients aged 12 and older living with hemophilia A or B.

This approval builds on our earlier indication for people living with hemophilia with inhibitors and reflects our continued commitment to expanding access and reimagining care across the hemophilia landscape.

Behind this milestone is a team of passionate, driven individuals who work tirelessly to bring innovative solutions to life. I am incredibly proud to be part of this journey—one that’s focused on delivering better options and more control for people navigating life with hemophilia. Thank you to the entire team who has contributed to this great achievement. Your dedication makes a real difference.”

Melissa Leichter proudly shares news on FDA Approvement for Alhemo.

Melissa Leichter Announces The Newly FDA Approved Subcutaneous Prophylactic Treatment for Hemophilia A or B